Efficacy of peficitinib in two patients with rheumatoid arthritis on maintenance hemodialysis

Objective: Treatment options for patients with rheumatoid arthritis on maintenance hemodialysis with an inadequate response to biologic agents have not been reported. In this report, we describe two patients who achieved remission after treatment with peficitinib.Methods: Two 69- and 85-year-old patients with rheumatoid arthritis on maintenance hemodialysis were previously treated with biologics and started on peficitinib 100 mg/day after the secondary failure of biologics.Discussion: In the two cases presented here, rheumatoid arthritis was almost in remission and there were no adverse events, although the patients were switched to peficitinib after secondary failure of the biologic agents. Among Janus kinase inhibitors, peficitinib has the lowest renal excretion; therefore, its administration in patients on dialysis is not contraindicated according to the package insert in Japan. The use of biologic agents in patients on hemodialysis has been reported to be associated with a high incidence of infections; therefore, care should be taken to avoid infections when administering Janus kinase inhibitors.Conclusion: Janus kinase inhibitors with low renal excretion, such as peficitinib, may be effective in patients with rheumatoid arthritis on maintenance hemodialysis who have an inadequate response to biologic agents.     

Prior statin and short‐term outcomes of primary intracerebral hemorrhage: From a large‐scale nationwide longitudinal registry

IntroductionThe relationship between statins and intracerebral hemorrhage outcomes is unclear.AimWe aimed to compare the in‐hospital mortality and evacuation of intracranial hematoma rates in patients with primary intracerebral hemorrhage between prior statin users and nonusers.ResultsThe final study population included 66,263 patients. Multivariable logistics analyses showed that prior statin use was not associated with in‐hospital mortality for primary intracerebral hemorrhage (adjusted odd ratio 0.78, 95% CI 0.61–1.01), but reduced the proportion of patients undergoing evacuation of intracranial hematoma (adjusted odd ratio 0.70, 95% CI 0.61–0.82). Propensity score matching analyses yielded similar results.ConclusionPrior statin use was not associated with in‐hospital mortality but did reduce evacuation of intracranial hematoma rates.     

芳香化酶抑制剂来曲唑的研究进展

来曲唑是新一代强效的非甾体芳香化酶抑制剂,用于一线治疗晚期乳腺癌,并广泛用作乳腺癌的二线用药．疗效好,不良反应少,耐受性好．值得临床推广应用。本文综述了来曲唑的合成方法以及临床研究进展。     

心血管疾病干细胞治疗的疗效判断方法

干细胞治疗可增加冠状动脉血液灌注,增加心肌收缩力,在严重缺血性心脏病的治疗中发挥重要作用。本文对干细胞治疗的疗效判断方法及干细胞治疗对左心室功能、心肌灌注、心肌存活等的作用作一综述。     

PGK1-coupled HSP90 stabilizes GSK3β expression to regulate the stemness of breast cancer stem cells

Objective: Glycogen synthase kinase-3β(GSK3β) has been recognized as a suppressor of Wnt/β-catenin signaling, which is critical for the stemness maintenance of breast cancer stem cells. However, the regulatory mechanisms of GSK3β protein expression remain elusive.Methods: Co-immunoprecipitation and mass spectral assays were performed to identify molecules binding to GSK3β, and to characterize the interactions of GSK3β, heat shock protein 90(Hsp90), and co-chaperones. The role of PGK1 in Hsp90 ch...     

表皮生长因子受体抑制剂在胰腺癌治疗中的作用

胰腺癌是常见的消化道恶性肿瘤,传统的化疗和放疗效果均不甚理想。表皮生长因子受体(EGFR)信号转导通路在胰腺癌细胞的增殖、转移、血管形成等方面有重要作用,因此,针对EGFR信号通路的新型药物已陆续开发和应用。此文综述了EGFR的结构、功能以及EGFR抑制剂在胰腺癌治疗中的作用。     

Tumor’host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds

Targeting of the tumor stroma, including the tumor vasculature, represents a new frontier in the treatment of malignancy. Preclinical studies and clinical experiences have established that stroma-directed novel agents must be combined with conventional therapies in order to achieve relevant therapeutic efficacy. Here we review our preclinical experience on combinations of paclitaxel with a tyrosine kinase receptor inhibitor of angiogenesis (SU6668) and a vascular disrupting agent (VDA, ZD6126), and discuss the critical factors that determine the outcome of these treatments. We also analyze the relevance of the intrinsic sensitivity of the tumor to the drugs, as well as the possibility that the two combined agents synergistically affect the vasculature or independently target the host and the tumor compartments. Finally, we discuss the need to carefully optimize scheduling and sequencing, through the use of reliable end points, in order to avoid negative pharmacological interactions and to improve the antineoplastic efficacy of paclitaxel-based combination treatments.     

Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis

Objective  To assess the effects of aromatase inhibitors in women symptomatic of pain with endometriosis.
Design  A systematic review of published literature.
Material and methods  We conducted a comprehensive literature search to identify all the published observational and randomised studies evaluating the efficacy of aromatase inhibitors on pain associated with endometriosis. A combination of keywords was used to identify the maximum number of relevant citations in MEDLINE, EMBASE, CINAHL and the Cochrane Database.
Outcome  Pain relief, lesion size and quality of life.
Results  There were eight studies (137 women) evaluating outcomes of aromatase inhibitors. In case series/reports (seven studies, 40 women), aromatase inhibitors combined with progestogens or oral contraceptive pill or gonadotrophin-releasing hormone (GnRH) analogues reduced mean pain scores and lesion size and improved quality of life. An RCT (97 women) demonstrated that aromatase inhibitors in combination with GnRH analogues significantly improved pain ( P < 0.0001) compared with GnRH analogues alone together with significant improvement in multidimensional patient scores ( P < 0.0001). There was no significant reduction in spine or hip-bone densities.
Conclusion  Aromatase inhibitors appear to have a promising effect on pain associated with endometriosis, but the strength of this inference is limited due to a dearth of the evidence available.